ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that it will give a presentation at the European Society of Ophthalmology Congress, which is held from June 10-13 in Barcelona, Spain.
The presentation "The industry pipeline for diabetic macular edema (DME), what does it hold?" will be given by Jean Feyen, PhD, Head of R&D at ThromboGenics. In his presentation, Dr Feyen will provide an overview of the current standard of care for DME, the unmet medical need, future treatments for DME currently under development and delivery mechanisms.
ThromboGenics has a pipeline of disease modifying drug candidates targeting the key segments of the diabetic eye disease market: non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, with or without DME.
Dr Feyen's presentation will take place from 11:00 - 11:15am CET, Tuesday 13 June.
"We are honored with this opportunity to join this prestigious meeting of the European Society of Ophthalmology", said Dr. Patrik De Haes, MD, CEO of ThromboGenics NV. "There is a clear unmet medical need for improved treatment options for diabetic eye disease in general, and diabetic macular edema specifically. Our current development pipeline is focused on addressing this need and we are currently developing 4 new disease modifying therapies, each with the potential to improve on the current standard of care for a number of diabetic eye disease indications."
ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.
ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopathy (NPDR).
ThromboGenics is conducting a Phase II clinical study evaluating THR- 317, a PlGF inhibitor for the treatment of diabetic macular edema, as a stand-alone or as a combination therapy with anti-VEGF treatments. In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos, are in late stage pre-clinical development.
ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of symptomatic vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US. Novartis commercializes JETREA® outside the United States.
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.
More information is available at www.thrombogenics.com